Application No.: NEW Docket No.: 2294-0119PUS1

AMENDMENTS TO THE CLAIMS

1. (Original) A pharmaceutical composition comprising a statin and an antiflatulent agent in a suitable proportion as active ingredient.

- 2. (Original) A pharmaceutical composition according to claim 1 wherein the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, and pharmaceutically acceptable salts and hydrates thereof.
- 3. (Original) A pharmaceutical composition according to claim 2 wherein the statin is simvastatin or a pharmaceutically acceptable salt thereof.
- 4. (Original) A pharmaceutical composition according to any one of claims 1 to 3 wherein the antiflatulent agent is selected from the group consisiting of simethicone and dimethicone.
- 5. (Original) A pharmaceutical composition according to claim 4 wherein the antiflatulent agent is simethicone.
- 6. (Currently Amended) A pharmaceutical composition according to any one of the preceding claims claim 1 wherein the composition is a tablet, capsule, syrup, solution, powder, granule, or emulsion.
- 7. (Original) A pharmaceutical composition according to claim 6 wherein the tablet is a coated tablet.
- 8. (Original) A pharmaceutical composition according to claim 7 wherein the coated tablet comprises a core and a coating, the core comprising the statin and the antiflatulent agent.
- 9. (Currently Amended) A pharmaceutical composition according to any one of the preceding claims claim 1, wherein the weight ratio of antiflatulent agent versus statin is at

Application No.: NEW Docket No.: 2294-0119PUS1

least 0.25.

- 10. (Currently Amended) A pharmaceutical composition according to any one of the preceding claims claim 1, wherein the weight ratio of antiflatulent agent versus statin is at least 1,50.
- 11. (Original) A pharmaceutical composition according to claim 6 or 7 wherein simvastatin is present in an amount from 2.5 to 100 mg per tablet.
- 12. (Original) A pharmaceutical composition according to claim 11 wherein simvastatin is present in an amount from 5 to

80 mg per tablet.

- 13. (Original) A pharmaceutical composition according to claims 6 or7 wherein simethicone is present in an amount from 25 to 250 mg per tablet.
- 14. (Original) A pharmaceutical composition according to claim 13 wherein simethicone is present in an amount of 125 mg per tablet.
- 15. (Currently Amended) A pharmaceutical composition according to any one of the preceding claims claim 1 further comprising one or more diluents, one or more binders, one or more disintegrants and one or more lubricants.
- 16. (Original) A pharmaceutical composition according to claim 15 wherein the diluent is selected from the group consisting of microcrystalline celluloses and their derivatives, lactose, mannitol, calcium phosphates, starch, and the mixtures thereof.
- 17. (Original) A pharmaceutical composition according to claim 15 wherein the binder is selected from the group consisting of starch, polyethylene glycols, polyvinylpyrrolidones, cellulose derivatives, and the mixtures thereof.

3 MSW/sns

18. (Original) A pharmaceutical composition according to claim 15 wherein the disintegrant is selected from the group consisting of colloidal silicon dioxide, croscarmellose, la polyvinylpyrrolidone, starch and its pregelatinized derivatives, and the mixtures thereof.

19. (Original) A pharmaceutical composition according to claim 15 wherein the lubricant is

- selected from the group consisting of talc, magnesium stearate, stearic acid, sodium stearyl fumarate, PEG 8000, and the mixtures thereof.
- 20. (Currently Amended) A pharmaceutical composition according to any one of the preceding claims claim 1 further comprising one or more antioxidants and one or more wetting agents.
- 21. (Original) A pharmaceutical composition according to claim 7 wherein the coating of the tablet comprises a cellulose derivative or its pharmaceutically.
- 22. (Original) A pharmaceutical composition according to claim 21 wherein the cellulose derivative is hydroxypropyl methylcellulose.
- 23. (Currently Amended) A pharmaceutical composition according to any one of the preceding claims claim 1 further comprising one or more colouring agents.
- 24. (Currently Amended) A process for preparing a pharmaceutical composition according to any one of the preceding claims claim 1 by direct compression of components thereof.